Status:
UNKNOWN
Identification and Treatment of the Liability to Develop Schizophrenia
Lead Sponsor:
Central South University
Collaborating Sponsors:
Ortho-McNeil Janssen Scientific Affairs, LLC
Conditions:
Schizophrenia
Eligibility:
All Genders
19-59 years
Phase:
PHASE4
Brief Summary
This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in t...
Eligibility Criteria
Inclusion
- Having at least one first-degree biological relative with schizophrenia and their age is between 19 and 59.
- Desire to participate in a medication trial.
- Is able to provide informed consent.
- Having moderate levels of negative symptoms, defined as 6 items rated 3 or higher on the Scale for the Assessment of Negative Symptoms (SANS).
- Scoring two or more standard deviations below normal in at least one of three cognitive domains: vigilance/working memory, long-term verbal memory, and executive functions.
- Scoring at least one standard deviation below normal in a second cognitive domain.
Exclusion
- IQ less than 80.
- Formal education less than 10 years.
- History of psychotic disorders.
- History of treatment with an antipsychotic medication.
- A substance abuse diagnosis within 6 months of diagnosis.
- A head injury with documented loss of consciousness exceeding 5 minutes (or subsequent cognitive deficits).
- A history of neurologic disease or damage.
- A medical condition with significant cognitive sequelae.
- A history of electroconvulsive treatment.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00305474
Start Date
December 1 2003
Last Update
June 24 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mental Health Institute
Changsha, Hunan, China, 410011